Abstract
Little is known of the effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on the renal tubules. We investigated the effect of the SGLT2 inhibitor, tofogliflozin (TOFO) on renal tubular indices, according to the degree of albuminuria, in type 2 diabetes mellitus (T2DM) patients with preserved renal function. A total of 988 patients, receiving TOFO, were enroled and divided into 3 groups, based on the urine albumin-to-creatinine ratio (UACR). The tubular indices (urinary N-acetyl-beta-d-glucosaminidase [NAG]-to-creatinine and urinary beta-2 microglobulin [beta2MG]-to-creatinine ratios) and UACR were log-transformed in the correlation analysis. Treatment with TOFO led to similar reductions in glycated haemoglobin (HbA1c) levels, from baseline to week 24, across all groups. The NAG level increased in the normoalbuminuria group and decreased in the macroalbuminuria group significantly (P < .001, both), but did not change in the microalbuminuria group. Significant reductions in the UACR were observed in both microalbuminuria and macroalbuminuria groups (P < .001, both). Significant negative correlations between changes in the NAG and beta2MG levels and their corresponding baseline values were observed in all participants. Th...Continue Reading
References
Jan 20, 1999·Kidney International·K MorriseyA O Phillips
Mar 13, 1999·Annals of Internal Medicine·A S LeveyD Roth
May 28, 2005·Diabetes·Michael Brownlee
Nov 25, 2005·Diabetes·Hassan RahmouneJohn Brown
Aug 21, 2007·Current Drug Targets·Sho-ichi YamagishiSeiya Okuda
Feb 19, 2008·Diabetologia·R G LanghamR E Gilbert
Jul 9, 2008·Nature Clinical Practice. Endocrinology & Metabolism·Suma DronavalliGeorge L Bakris
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Sep 24, 2011·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Scott C ThomsonPrabhleen Singh
Feb 18, 2012·Annual Review of Physiology·Volker Vallon, Scott C Thomson
Mar 24, 2012·Diabetes Research and Clinical Practice·Sang Soo KimYong Ki Kim
Aug 16, 2012·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Masaru HorioUNKNOWN Collaborators Developing the Japanese Equation for Estimated GFR
Nov 16, 2012·American Journal of Physiology. Renal Physiology·Volker VallonTimo Rieg
Mar 20, 2013·Diabetes/metabolism Research and Reviews·Sayaka MaedaSho-ichi Yamagishi
Dec 18, 2013·Circulation·David Z I CherneyMaximilian von Eynatten
Jan 11, 2014·Journal of the American Society of Nephrology : JASN·Landon E DicksonBruce A Molitoris
Feb 12, 2014·Expert Opinion on Pharmacotherapy·Yukio TanizawaUNKNOWN Tofogliflozin 004 and 005 Study group
Apr 1, 2014·Cardiovascular Diabetology·Kohei KakuUNKNOWN Tofogliflozin 003 Study Group
Jun 25, 2014·PloS One·Naoto TeramiHirofumi Makino
Oct 5, 2014·Diabetologia·Marko SkrtićDavid Z I Cherney
Jul 17, 2015·Diabetes, Obesity & Metabolism·S IkedaT Kadowaki
Aug 1, 2015·Rejuvenation Research·Sho-ichi Yamagishi, Takanori Matsui
Mar 22, 2016·PloS One·Masanori WakisakaMototaka Yoshinari
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Jun 19, 2016·Diabetologia·David CherneyMaximilian von Eynatten
Apr 4, 2017·Diabetes, Obesity & Metabolism·Yasuo TerauchiKohei Kaku
Jun 13, 2017·The New England Journal of Medicine·Bruce NealUNKNOWN CANVAS Program Collaborative Group
Citations
Apr 5, 2019·Diabetes, Obesity & Metabolism·Kiyohide NunoiHideki Suganami
Feb 9, 2020·Journal of Diabetes Investigation·Kazunori UtsunomiyaKohei Kaku
Jul 30, 2020·Diabetes Technology & Therapeutics·Kazuo KobayashiAkira Kanamori
Nov 30, 2021·International Urology and Nephrology·Homare ShimohataMasaki Kobayashi